Currently, the global population affected by autoimmune diseases has exceeded 500 million, covering hundreds of distinct disease entities. For a long time, therapeutic strategies have primarily focused on controlling inflammation and slowing disease progression, rather than addressing the underlying immunological dysfunction.

However, as the central role of B cells in multiple diseases continues to be validated, the therapeutic paradigm is undergoing a fundamental shift—from long-term immunosuppression toward immune system reconstitution.

At the same time, the role represented by global pharmaceutical distributor DengYueMed is gradually evolving from a traditional pharmaceutical distribution link into a critical infrastructure layer connecting innovative therapies with global clinical accessibility.

B Cells as a Therapeutic Core: From Inflammatory Outcome to Disease Engine

Traditional autoimmune treatment frameworks have largely relied on broad immunosuppressants and anti-inflammatory agents, such as corticosteroids, methotrexate, and TNF-α inhibitors.

Although these therapies can rapidly control symptoms, they do not address the fundamental issue of immune system misrecognition of self-antigens.

With advances in immunology research, B cells have been redefined as core drivers in multiple autoimmune diseases rather than mere downstream effector cells. Their mechanisms of action can be summarized in three key dimensions:

1.  B cells are the primary source of autoantibody production

2.  B cells participate in antigen presentation and T-cell activation

3.  B cells amplify inflammatory responses through cytokine secretion

This multi-layered functionality positions B cells as a high-value upstream therapeutic target.

The anti-CD20 monoclonal antibody Rituximab first clinically validated this therapeutic logic, demonstrating significant improvements in disease activity in Rheumatoid Arthritis and Systemic Lupus Erythematosus.

Subsequently, second-generation agents such as Ocrelizumab and Ofatumumab further optimized depletion efficiency and administration routes, gradually becoming standard-of-care options in Multiple Sclerosis.

However, a clear limitation remains: anti-CD20 therapies primarily target circulating mature B cells and do not fully eliminate long-lived plasma cells or deep immune memory compartments. As a result, disease relapse is commonly observed after treatment discontinuation.

This has driven the field toward a more radical question: can deeper immune depletion enable disease-level reset?

CAR-T as Proof of Immune Reset: From Disease Control to Systemic Rebuilding

The introduction of CAR-T cell therapy has provided the first experimental foundation for systemic immune reset in autoimmune diseases.

In 2022, the team led by Georg Schett applied CD19 CAR-T therapy in patients with refractory Systemic Lupus Erythematosus, observing sustained drug-free remission following profound B cell depletion.

This result provided the first clinical evidence in human disease that the immune system can re-establish immune tolerance after being comprehensively reset.

Further studies in Multiple Sclerosis and other diseases have shown that CAR-T therapy not only reduces disease activity but may also alter long-term disease trajectories.

This breakthrough redefined therapeutic objectives across three levels:

1.  From suppressing immune responses

2.  To eliminating pathogenic B cell lineages

3.  To attempting reconstruction of immune homeostasis

However, CAR-T also faces significant practical limitations, including long individualized manufacturing cycles, high costs, and strong dependence on specialized healthcare infrastructure, making large-scale deployment in chronic autoimmune diseases challenging.

As a result, the industry has shifted toward a more practical question: how can efficacy be maintained while achieving scalability?

Technological Divergence: Structural Trade-offs Between Efficacy Depth and Accessibility

Following validation that deep B cell depletion via CAR-T can trigger immune reset, industry competition has shifted from efficacy validation to scalability optimization.

Three major technological pathways have emerged, each reflecting different assumptions about the eventual end-state of therapy.

1. Autologous CAR-T: Efficacy-Depth-First Pathway

Autologous CAR-T uses the patient’s own T cells for ex vivo engineering and represents the most potent B cell depletion strategy currently available.

Key characteristics include:

● Achieves the most complete B cell lineage depletion

● Closest approach to functional cure at the mechanistic level

● Demonstrated immune reset potential in Systemic Lupus Erythematosus and Multiple Sclerosis

However, structural constraints remain:

● Complex individualized manufacturing process

● Long production timelines

● High per-patient cost limiting scalability

As a result, this approach is most likely to achieve initial breakthroughs in severe, refractory, and low-prevalence but high-value indications.

2. Allogeneic CAR-T: Scalability-First Pathway

Allogeneic CAR-T utilizes donor-derived T cells as a standardized source, aiming to enable off-the-shelf cell therapy.

Its main advantages include:

● Significantly reduced production cost

● Shorter treatment timelines enabling immediate availability

● Greater scalability for commercial deployment

However, key challenges remain:

● Limited in vivo persistence

● Susceptibility to host immune rejection

● Uncertain durability of therapeutic response

The central industry question is whether a sufficiently deep, short-duration B cell depletion event can still trigger durable immune system reset and long-term remission.

3. Multispecific Antibodies: Standardized Pharmaceutical Pathway

Non-cell therapies represented by bispecific antibodies are emerging as the closest modality to conventional drug development in B cell depletion strategies.

Representative agents include Blinatumomab and Teclistamab.

Key characteristics:

● Recruit T cells to target B cells through antibody engineering

● No complex cell manufacturing required

● Enables repeat dosing and chronic disease management models

Advantages include:

● Mature manufacturing infrastructure

● High accessibility

● Easier integration into large-scale healthcare systems

Their main limitation lies in relatively lower depletion depth and shorter duration of response, making them more suitable for disease activity control rather than immune system reset.